As opposed to the Philadendia-positive myeloid neoplasm, namely CML, the MPNs are characterized by different somatic genetic mutations involving JAK2, Calreticulin (CALR) and the thrombopoietin receptor (MPL) encoding genes [20]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.